Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 29, 2018 07:00 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals to Participate in Two Healthcare Investor Conferences in September

HOUSTON, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
August 07, 2018 16:05 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Reports Second Quarter 2018 Financial Results

HOUSTON, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
August 06, 2018 07:00 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Appoints Dr. Thierry Darcis as General Manager of Europe to Lead the Anticipated Launch of BPX-501

HOUSTON, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
July 31, 2018 07:00 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 7, 2018

HOUSTON, July 31, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
July 16, 2018 16:25 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Announces Departure of Chief Financial Officer

HOUSTON, July 16, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
May 30, 2018 07:00 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference

HOUSTON, May 30, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
May 29, 2018 07:00 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Appoints Shane Ward as General Counsel

HOUSTON, May 29, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
May 17, 2018 09:20 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Announces Clinical Presentations on Lead Product Candidate BPX-501 at the 23rd Congress of the European Hematology Association

HOUSTON, May 17, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
May 15, 2018 07:00 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Announces Oral Presentation on Dual-Switch CAR-T Technology at the 21st Annual Meeting of the American Society of Gene and Cell Therapy

HOUSTON, May 15, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
May 08, 2018 16:01 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Reports First Quarter 2018 Financial Results

HOUSTON, May 08, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right